IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.48
+0.24%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.08
- Revenue estimate
- $59.2M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.22
- EPS estimate
- -$0.08
- Revenue actual
- $51.2M
- Revenue estimate
- $49.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 9
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -42.5%
- Revenue beats (12Q)
- 8
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.08 | -$0.22 | Miss -175.00% | $51.2M |
| May 7, 2026 | -$0.08 | -$0.09 | Miss -12.50% | $44.2M |
| Mar 3, 2025 | -$0.26 | -$0.15 | Beat 42.31% | $7.6M |
| May 9, 2024 | -$0.16 | -$0.20 | Miss -25.00% | $40.0K |
| Mar 19, 2024 | -$0.18 | -$0.19 | Miss -5.56% | $139.0K |
| May 11, 2023 | -$0.27 | -$0.27 | In line | $360.0K |
| Mar 1, 2023 | -$0.22 | -$0.27 | Miss -22.73% | $73.0K |
| Nov 9, 2022 | -$0.23 | -$0.28 | Miss -21.74% | $118.0K |
| Mar 1, 2022 | -$0.21 | -$0.23 | Miss -9.52% | $390.0K |
| Nov 12, 2021 | -$0.20 | -$0.22 | Miss -10.00% | $66.0K |
| Aug 12, 2021 | -$0.12 | -$0.23 | Miss -91.67% | $339.0K |
| May 14, 2021 | -$0.41 | -$0.21 | Beat 48.78% | $139.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026